Orchid Pharma's Q2 FY 2025-26 Quarterly Results
- 13 Nov 2025
Result Summary
- Orchid Pharma Ltd reported a 10.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.3%.
- Its expenses for the quarter were up by 21.7% QoQ and 1.6% YoY.
- The net profit decreased 138.4% QoQ and decreased 121.0% YoY.
- The earnings per share (EPS) of Orchid Pharma Ltd declined at 1.13 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 204.30 | 184.38 | 230.22 | 10.8% | -11.3% |
Total Expenses | 207.63 | 170.66 | 204.32 | 21.7% | 1.6% |
Profit Before Tax | -3.33 | 13.71 | 25.90 | -124.3% | -112.9% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -5.72 | 14.91 | 27.24 | -138.4% | -121.0% |
Earnings Per Share | -1.13 | 2.94 | 5.37 | -138.4% | -121.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Orchid Pharma Ltd is a pharmaceutical company that is primarily engaged in the manufacturing and sale of pharmaceutical products. The company operates within the pharmaceutical industry, focusing on the development and commercialization of active pharmaceutical ingredients (APIs) and finished dosage forms. Orchid Pharma has been involved in the production of a wide range of antibiotics and other pharmaceutical products. As of the data available, there are no specific recent major developments highlighted, but the company continues to operate within its established industry.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Orchid Pharma Ltd reported total income of ₹204.30 crores. This represents a quarter-over-quarter (QoQ) increase of 10.8% from ₹184.38 crores in the first quarter of fiscal year 2026 (Q1FY26). However, when comparing year-over-year (YoY), there was a decrease of 11.3% from ₹230.22 crores in Q2FY25. The data indicates a recovery in revenue on a quarterly basis from the previous quarter, though the company experienced a decline compared to the same quarter of the previous year.
Profitability
For Q2FY26, Orchid Pharma Ltd recorded a loss in profitability with a Profit Before Tax (PBT) of -₹3.33 crores, significantly down from a profit of ₹13.71 crores in Q1FY26 and ₹25.90 crores in Q2FY25. This reflects a QoQ decline of 124.3% and a YoY decline of 112.9%. Consequently, the Profit After Tax (PAT) for Q2FY26 was -₹5.72 crores, compared to ₹14.91 crores in Q1FY26 and ₹27.24 crores in Q2FY25, marking declines of 138.4% QoQ and 121.0% YoY. Earnings per Share (EPS) followed a similar trend, recorded at -₹1.13 for Q2FY26, down from ₹2.94 in Q1FY26 and ₹5.37 in Q2FY25, with QoQ and YoY declines mirroring those of PAT.
Operating Metrics
Total expenses for Orchid Pharma Ltd in Q2FY26 were ₹207.63 crores, reflecting a significant increase of 21.7% from ₹170.66 crores in Q1FY26 and a slight increase of 1.6% from ₹204.32 crores in Q2FY25. The company did not incur any tax expenses across the periods under review. The data suggests that while total income saw an increase on a quarterly basis, the rise in expenses was more pronounced, thereby impacting profitability for the quarter. There are no additional operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio provided in the available data to further analyze the operational efficiency or financial leverage of the company.